UTICA, NY–(Marketwire – November 30, 2010) – CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company has amended its existing senior credit facilities to provide for a five-year, $250 million senior secured revolving credit facility. The term loans currently outstanding will remain in place. A group of ten financial institutions have agreed to participate in the revolving credit facility, with JP Morgan Chase Bank, N.A. as Administrative Agent. The revolving credit facility was arranged by J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (successor by merger to Banc of America Securities LLC) as joint lead arrangers and joint bookrunners.

The amendment increases the revolving line of credit to $250 million and extends its term to November 30, 2015. Interest on drawn amounts is based on a pricing grid determined by the Company’s senior secured debt leverage ratio. At the present leverage ratio, interest cost is equal to LIBOR plus 1.75% and the fee on undrawn commitments is equal to 25 basis points. The agreement also permits a $75 million expansion of the revolver with consent of lenders participating in the expansion.

“We are pleased that our bank lenders have provided this increased credit facility with terms we consider favorable to CONMED,” said Mr. Joseph J. Corasanti, President and Chief Executive Officer. “We do not anticipate that interest expense will be materially affected by the new revolver.”

The new facility will be used to refinance the existing $49 million outstanding on the previous revolving credit facility, eliminate the previous receivable financing facility and for general corporate purposes. It is also intended to provide liquidity should the Company be required to fund the $112 million face amount of 2.5% Senior Subordinated Notes which are puttable on November 15, 2011. 

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of sports medicine-arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. Surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology use the Company’s medical devices. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward Looking Information

Certain statements made herein constitute forward-looking statements. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. They are based upon management’s expectations and involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements therein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to: (i) the failure of any one or more of management’s assumptions to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and Quarterly Reports on Form 10-Q; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition (and its integration) or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation, or litigation; and/or (viii) the Company’s ability to devise and execute strategies to respond to market conditions.

AUSTIN, TX–(Marketwire – November 30, 2010) – ProAssurance Corporation (NYSE: PRA) today completed its previously announced acquisition of American Physicians Service Group, Inc. (“APS”) (NASDAQ: AMPH). As a result of the merger, APS is now a wholly-owned subsidiary of ProAssurance.

The Chairman and Chief Executive Officer of APS, Ken Shifrin, said, “We’ve found the ideal partner to carry on the physician-focused traditions of APS. We know that ProAssurance will continue to serve our 6,800 insureds with the individual attention that is a part of our mutual corporate cultures. The last decade has resulted in a spectacular 36% average annual increase in APS’ stock price, from $1.50 to $32.50, and I want to thank our shareholders for their trust and for the opportunity to lead the company during this exciting time. I also want to say what an honor it has been to work with the board of directors and employees of APS and to thank them for their loyalty and dedication.”

“We are excited about the opportunities this transaction creates for us,” said ProAssurance’s Chairman and Chief Executive Officer, W. Stancil Starnes. “Not only does it give us significant market presence as the second largest writer of medical professional liability (MPL) insurance in Texas, it also enhances our presence in Oklahoma and Arkansas. We expect to leverage the skill and dedication of APS’ employees to deliver an unmatched level of service and financial strength to policyholders in these three key states. Additionally, we believe our shareholders will see benefits as well, as we expect to grow profitably during a challenging time in our business.”

Under the terms of the merger, each share of APS stock was redeemed for $32.50 in cash. Shareholders whose stock is held by a broker or in direct registration will be paid automatically. Those APS shareholders with stock certificates will receive instructions by mail for surrendering their shares in order to receive payment. Shareholders with questions about the share conversion process may contact American Stock Transfer & Trust at (877) 248-6417.

As a result of this transaction, APS’ common stock will cease to trade on the Nasdaq Stock Market prior to the open of business on December 1, 2010, and will thereafter be delisted.

About APS

APS is an insurance holding company with subsidiaries that provide medical malpractice insurance for physicians and other healthcare providers. APS is headquartered in Austin, Texas. Further information about the company is available on the Internet at www.amph.com.

PRINCETON, NJ–(Marketwire – November 30, 2010) –  To assist companies in managing their healthcare insurance options and show third party administrators (TPA), insurers and physicians how to react appropriately, Health Options Worldwide (HOW), an online vacation surgery resource, is offering a free webinar. Titled “Health Care Trends and Employers: New Strategies for a Changing Marketplace,” the webinar takes place Thursday, December 2nd, at 10 am EST and 4 pm EST. HOW, an international and domestic medical travel and medical tourism agency, will cover the current state of the healthcare marketplace as well as value-based and competitively priced key service to businesses.

Participants can register for 10am EST: https://www3.gotomeeting.com/register/526273158

Participants can register for 4pm EST: https://www3.gotomeeting.com/register/505357078

If participants have any questions or problems registering for the webinar, please contact Chris Peterson at 1-877-234-1345 or via email at: [email protected]. For more information, visit the HOW website at: www.healthoptionsworldwide.com

“Due to rising healthcare costs, companies need new strategies to reduce healthcare spending, improve the quality of care, and educate employees to take a more active role in their healthcare. Employers are afraid of the high costs that come with a self-funded employer solution, but yet they still want to provide health insurance coverage for their employees,” said David Goldstein, president of HOW.

Words like high deductible health plan surgery and voluntary surgery networks will become very popular in the healthcare market. As employee benefits claims and costs continue to rise, employers, TPAs and doctors can benefit from this webinar, says Goldstein. Employers can learn new ways to control risk and encourage employees to become more proactive in managing their healthcare and healthcare spending.

Current healthcare reform stipulations have not reduced claims or costs. Inflation, increased use of services, aging population, changes in provider treatment patterns, medical technology and drug therapy improvements have also influenced the upward healthcare spending trend. “The cost of employer health plans will probably increase within the next six months,” said Goldstein, quoting a survey by Wells Fargo Insurance Services.

Value based healthcare plans and supplemental healthcare solutions are affordable coverage options for businesses that can benefit workers. An increasing number of employers are researching different types of health insurance plans for their employees, knowing they can help them in many different ways.

“HOW leverages the growing trend of consumer-driven health care by connecting patients with physicians that offer high quality, low cost healthcare in the United States as well as internationally,” said Goldstein. He continued by saying that medical tourism will definitely affect the next generation of PPO’s by giving employees more local and regional treatment options with substantial discounts and improved outcomes.

Click here to see all recent news from this company

ATLANTA,GA–(Marketwire – November 30, 2010) – Clinigence, LLC, a health information technology company focused on the development of clinical business intelligence tools for accountable care organizations (ACOs) and healthcare providers, today announced that Steven M. Ornstein, M.D. has joined the Clinigence Advisory Board overseeing the development of the Clinigence collaborative software-as-a-service (SaaS) platform, helping care providers deliver quality care cost-efficiently.

Dr. Ornstein is a professor at the Department of Family Medicine and Graduate Studies at the Medical University of South Carolina (MUSC) in Charleston. He is also the founder and director of the Practice Partner Research Network (PPRNet) — the nation’s oldest and one of the largest practice-based research networks, operating for over 15 years and covering over 140 practices, 740 care providers and 1.8 million patients in 38 states.

Dr. Ornstein received his BA degree from Dartmouth in 1978 and his MD degree from Duke in 1981. He completed his residency in family practice at MUSC in 1985. He is board certified in family practice and has practiced continuously at MUSC Medical Center since 1985. Dr. Ornstein is a member of the American Academy of Family Physicians. He has led and participated in dozens of research studies on improving the quality of care through prevention, patient engagement and adherence, evidence-based guidelines and the use of information technology. At PPRNet, Dr. Ornstein has pioneered and perfected the translation of research into clinical practice to achieve real, measurable improvements in patient care.

“We are extremely pleased to welcome Dr. Ornstein to our advisory board,” said Kobi Margolin, Clinigence’s CEO. “We believe that his depth of knowledge in the area of translating scientific evidence into real-life improvement in patient outcomes will help us achieve the full potential of our unique and timely clinical business intelligence platform.”

About Clinigence

Clinigence, LLC, in Atlanta, is a health information technology company. Conceived in 2009 and launched in 2010, Clinigence develops, publishes and delivers collaborative software-as-a-service (SaaS) to help healthcare providers derive business value from clinical data and quality patient care. The Clinigence solution is tailored to the emerging needs of healthcare providers due to the shift of the US healthcare system from volume- to value-based purchasing and the growing demand for quality patient care. More information can be found at http://www.clinigence.com or contact Kobi Margolin at [email protected] or +1-678-466-6650.

CINCINNATI, OH–(Marketwire – November 30, 2010) –  “Using Benchmarks: The Good, The Bad, and The Ugly,” a new guide from Compass Clinical Consulting authored by Shawna O’Neill, RN, MHA; Eric Dam, MHA and Compass Clinical President Cary Gutbezahl, MD, reveals the positives and negatives of hospital benchmarking.

THE BENCHMARKING PROBLEM — ONE-DIMENSIONAL MEASUREMENT

Measurement is the cornerstone of assessing the performance of a hospital department. But, the problem is that benchmarks are one-dimensional, while real work is not. Designing productivity processes using benchmarks can cause problems if not done correctly.

BUILDING A CULTURE OF PRODUCTIVITY

“Using Benchmarks: The Good, The Bad, and The Ugly” shows how hospital leaders and managers can employ benchmarks to build a culture of productivity and provides strategies to:

• Help struggling managers meet their productivity targets while gaining buy-in from staff members
• Optimize workforce productivity using realistic benchmarks as guidelines, not mandates
• Ensure that leaders, managers, and employees “speak the same language” by establishing common definitions of key terms
• Create appropriate staffing levels to meet department workloads

ADD VALUE AT EVERY STEP

In hospital productivity design, every step within every process change should add value to the patients and the financial stability of the hospital. Whether you choose to approach productivity department by department or house-wide, the strategies in “Using Benchmarks: The Good, The Bad, and The Ugly” will guide your productivity transformation process.

To learn more download “Using Benchmarks: The Good, The Bad, and The Ugly.”

RELATED LINKS:

• Hospital Productivity Without Fear 
• Hospital Decisions Today Will Shape Your Hospital’s Future Workforce

About Compass Clinical Consulting
Compass Clinical Consulting helps hospitals reduce the cost of providing safe, quality patient care. Founded in 1979 and based in Cincinnati, OH, Compass has helped hundreds of hospitals and health systems prepare for accreditation, optimize labor cost management, manage clinical resources, and improve patient throughput and physician relations.

Click here to see all recent news from this company

DEURLE, BELGIUM–(Marketwire – November 30, 2010) – Remedent, Inc. (OTCBB: REMI), an international company specializing in research, development and the manufacture of oral care and cosmetic dental products signed an agreement with Small Caps Finance SA to open at least two Glamsmile Studios in Brussels, Belgium and Milan, Italy with an option for Rome, Italy as well.

SCF will provide all the necessary financing to a joint venture between both entities, where Remedent/Glamsmile will be the majority owner and provide all the necessary product and support to open the Studios. Glamsmile will operate and manage the Studios under the same formula for success as it does in Europe and Asia. It is anticipated that both Studios will open prior to the conclusion of our year end, namely March 31, 2011.

“The direct retail model of opening Studios in both Asia and Europe has been the reason for our financial turnaround as opposed to our previous wholesale (B2B) model via a distributor. This has led to two consecutive profitable quarters since the beginning of our financial year, April 1, 2010. In addition to western Europe, we will continue with our Glamsmile Studio expansion in Asia as well where we anticipate opening our Shanghai superstore in early 2011. I am very excited about our new venture with SCF for western Europe which will give us further exposure into two new markets, namely Milan and Brussels. The locations for our two new Studios have already been determined and they will be based in the most affluent shopping areas of both major cities. I look forward to the opening of both these two new locations where we expect the financial success to continue as we have experienced with our other Studios located in both Europe and Asia,” said Guy DeVreesse, the CEO of Remedent.

SCF currently has investments in both the pharmaceutical and health care industries. “The Glamsmile concept is unique and we are very excited about introducing beautiful smiles into new markets,” said Mr. Bernardo Ruzziconi, SCF, Chief Executive Officer.

About Remedent.

Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and domestic dentistry products. The company serves the professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 35 countries worldwide. For more information, go to www.remedent.com

Forward-Looking Statements

Statements in the press release that are “forward-looking statements” are based on the current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expect”, “intends,” “anticipate,” “anticipates,” “plans,” “projects,” “project,” to be uncertain and forward looking. Actual results could differ materially because of facts such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risks described in Remedent’s filings with the Securities and Exchange Commission, including but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of the press release.

LOS ANGELES, CA–(Marketwire – November 30, 2010) – MMRGlobal, Inc. (OTCBB: MMRF) (MMR) today announced it has signed a settlement agreement with the Lymphoma Research Foundation (LRF), resolving its lawsuit with LRF and giving the Company exclusive control of certain data and tissue samples created during trials of Favrille, Inc.’s FavId™ vaccine. The assets had been the subject of an ownership dispute with LRF. The Company acquired the FavId intellectual property, along with other biotech assets, from its reverse merger with Favrille, Inc., a San Diego biotech company, in January 2009. More than $140 million was spent on the development of the vaccine and other biotech assets and related patents. 

According to Kathleen M. Smith, a principal at Translational Medicine Consulting and a biorepository expert who provided expert testimony in the MMR litigation with LRF, the tissue samples could have values substantially in excess of one million dollars per set. When combined with clinical data and associated intellectual property belonging to MMR, the values could be significantly greater. 

“We will continue to explore licensing opportunities for these biotech assets, patents and other intellectual property with pharmaceutical companies, universities and institutional investors to create future streams of revenue for our shareholders,” said Robert H. Lorsch, MMRGlobal CEO. “I look forward to these assets being put to use to help find additional treatments for Non-Hodgkin’s Lymphoma and other related diseases while generating licensing revenues to help finance the Company’s primary business, namely the development and distribution of its MyMedicalRecords Personal Health Record and MMRPro Electronic Health Record products and services.”

MMR contended that prior to the merger, portions of the Company’s intellectual property were transferred by previous employees and or consultants of Favrille to third parties, including Lymphoma Research Foundation, without the knowledge and consent of Favrille’s Board of Directors or Science Committee. After MMR learned of the transfer, the Company pursued LRF to regain control of the data and tissue samples on behalf of its shareholders.

As part of the settlement agreement, the Lymphoma Research Foundation also settled a complaint filed in Los Angeles Superior Court by The RHL Group, Inc., a creditor of MMRGlobal, against LRF and others involving the transfer of the data, tissue samples and other assets which previously were the property of Favrille. Although The RHL Group case against LRF is settled, the case against the other named defendants is still active.

Over the last two years, MMRGlobal has been working to maximize the value of its biotech assets by perfecting its worldwide patent portfolio, regaining control of its anti-CD20 antibodies and FavId intellectual property including tissue samples, and developing licensing opportunities for the data and materials for use in Non-Hodgkin’s Lymphoma, target validation and other therapeutic research. As part of the settlement agreement, MMRGlobal shall cause the assets or portions of them to be used in further medical research.

About MMRGlobal, Inc.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc. (“MMR”), provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. MyMedicalRecords enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. The MyMedicalRecords Personal Health Record is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user’s account. The Company’s professional offering, MMRPro, is designed to give physicians’ offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients in real time through an integrated patient portal. MMR is an Independent Software Vendor Partner with Kodak to deliver an integrated turnkey EMR solution for healthcare professionals. MMR is also an integrated service provider on Google Health. To learn more about MMRGlobal, Inc. and its products, visit www.mmrglobal.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding MMRGlobal, Inc.’s assets including but not limited to its primary Health IT businesses, samples and data from vaccine and clinical trials, and anti-CD20 antibody assets. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related but not limited to changes in MMRGlobal, Inc.’s business prospects, its results of operations or financial condition, government regulation and changes in healthcare initiatives, developing and defending its intellectual property rights including those pertaining to the Company’s biotechnology assets, the development and approval of biotechnology/biopharmaceutical product candidates and Health IT products and such other additional risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. All subsequent written and oral forward-looking statements attributable to the Company (or any person acting on the Company’s behalf) are qualified by the cautionary statements in this notice. MMRGlobal, Inc. is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information.

Click here to see all recent news from this company

RALEIGH, NC–(Marketwire – November 30, 2010) – InoLife Technologies, Inc. (OTCBB: INOL), a service based healthcare products development, integration and marketing Company announced today that it will exhibit at the 18^th Annual World Congress on Anti-aging Medicine and Biomedical Technologies, (A4M) convention held at the Mandalay Bay Convention Center in Las Vegas, Nevada on December 9-11.

“This convention provides an excellent opportunity for our Company to expose our products to the medical community as well as the industry press,” stated Gary Berthold, CEO of InoLife Technologies, Inc. “We at InoLife Technologies would like to invite those health-care professionals that are attending the convention to visit booth 240 to discuss opportunities and for demonstrations of the Company’s DNA-based testing products.” 

InoLife will take advantage of this forum to educate physicians and healthcare practitioners on the advantages and availability of the Company’s Plavix metabolizing test. This DNA-based testing procedure can identify how a patient’s genetic inheritance may affect the body’s response to the popular drug commonly used for patients with cardiovascular risks.

The A4M expects approximately 3000 professionals to attend the convention. It is billed to be the largest and most influential conference and expo worldwide on preventative medicine and bio-medical technologies. The A4M organization is comprised of 22,000-plus members that include physicians, health practitioners, scientists, government officials and members of the general public representing over 105 nations. Eighty-five percent (85%) of the organization’s members are physicians (MD, DO,MBBS) followed by 12% that consists of scientists, researchers, and health practitioners, leaving 3% that are government officials, members of the working press and the general public. 

The A4M is dedicated to educating physicians, scientists and health practitioners on biomedical sciences, breaking technologies and anti aging issues. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

About InoLife Technologies, Inc.
InoLife is poised to become one of the premier U.S. marketers of state-of-the-art DNA-based test products. Positioned for growth and success in a burgeoning market, InoLife Technologies, www.inolifetech.com, is primarily focused on products, services and solutions that will enable state-of-the-art healthcare for today and the future for a diverse base of customers and end users. The Company’s mission is to identify, develop, integrate and bring to market innovative healthcare-based products and services that provide timely and practical solutions. The primary products and services that InoLife is currently addressing focuses upon those specific products and services that provide key solutions through the innovative use of specific DNA testing and Genetic analysis systems.

The principal customers of InoLife’s products and services are healthcare providers, physicians, practitioners, hospitals and outpatient facilities. InoLife will be marketing and distributing its products through traditional distribution channels. Additionally InoLife has developed certain products that can be sold directly to consumers and has created specific programs to reach those customers including e-commerce, direct sales, healthcare providers, pharmacies, distributors, retail sellers and specialty retailers.

TUSTIN, CA–(Marketwire – November 30, 2010) – Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today the signing of a Letter of Intent (“LOI”) to form an exclusive distribution agreement and collaborative business development partnership with Colombia-based PROCAPS S.A. PROCAPS is a top tier Latin American healthcare distribution company currently commercializing oncology and other therapeutic products throughout countries in Latin America.

RPC and PROCAPS intend to structure a long-term exclusive distribution partnership to build market share and awareness for RPC’s U.S. FDA-cleared Onko-Sure® In Vitro Diagnostic (IVD) cancer test in Latin America. The Companies are working on the following terms:

• RPC and PROCAPS will evaluate strategies to commercialize RPC’s Onko-Sure® IVD cancer test as a medically and economically beneficial cancer test for patients in Colombia and other Latin American healthcare markets.
• PROCAPS will investigate the market opportunity for full-service distribution of RPC’s Onko-Sure® IVD cancer test kit to clinical reference labs, hospitals and cancer treatment centers in designated territories in Latin America.
• RPC will grant PROCAPS first rights for distribution of Onko-Sure® in Colombia, Venezuela, Peru, Ecuador, Bolivia, Panama, Guatemala, Dominican Republic, and El Salvador.

In selecting PROCAPS, RPC acknowledges the Company’s expertise in launching new healthcare products in key Latin American markets. PROCAPS has formed successful partnerships with large pharmaceutical companies including Wyeth, Merck, GSK, and Sanofi. Most recently, PROCAPS has become an exclusive distributor of a US-developed oncology therapeutic.

RPC Chairman and CEO Mr. Douglas MacLellan commented, “Cancer knows no borders, and Radient Pharmaceuticals is well positioned to combat this disease by supplying innovative diagnostic tests like Onko-Sure® on both a domestic and global level. Latin America has an escalating cancer challenge similar to other emerging economies and in working with PROCAPS S.A., RPC holds tremendous commercialization potential for the rapidly expanding Latin American healthcare market. We are eager to finalize our partnership with PROCAPS and begin the marketing and sales of Onko-Sure in this region.”

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – November 29, 2010) – ForceLogix Technologies Inc. (TSX-V: FLT) is pleased to announce that it filed its interim financial statements and Management’s Discussion and Analysis today for the quarter ended September 30, 2010. The financial statements are available for review on SEDAR, www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to see all recent news from this company

WESTPORT, CT–(Marketwire – November 29, 2010) – African community groups are transforming the future for orphans and other children affected by HIV and AIDS thanks to U.S.-funded programs, Save the Children said.

“The United States is doing much more than providing lifesaving drug treatment when it comes to helping people around the world battle the AIDS crisis and it must continue to do so,” said Charles MacCormack, President and CEO of Save the Children. “One of the most remarkable changes is the creation of African community networks dedicated to supporting orphans and other children affected by HIV and AIDS.”

“It’s amazing how care and support can replace stigma and isolation when local groups are empowered to mobilize around children who have been orphaned and left vulnerable by HIV and AIDS,” MacCormack said.

More than 17 million children have lost one or both parents to AIDS. Many millions more children have reduced opportunities in life because HIV and AIDS have struck their families and communities. Most of these children are in Africa.

The United States President’s Emergency Plan for AIDS Relief (PEPFAR) has funded programs offering care and support to more than 3.6 million orphans and vulnerable children in Africa. Save the Children has led several of these large programs in Mozambique, Uganda, and Ethiopia and has put special emphasis on empowering local community groups to care for affected children. The result is sustainable change for children.

For World AIDS Day (Dec. 1), Save the Children has released a new multimedia video highlighting new hope for orphans and other children affected by AIDS in Ethiopia, where 530,000 children have benefited from U.S.-funded programs. 

“One of the most interesting changes involves Ethiopia neighborhood associations that originally formed to help poor families cover funeral expenses,” MacCormack said. “Today these groups have transformed to offer new hope to the living. They are helping children get an education, enough to eat, a place to live, and, perhaps most importantly, a renewed sense of community and loving support that they had lost to AIDS.”

See the video and learn how you can help support children affected by HIV and AIDS here:
www.savethechildren.org/worldAIDSday2010

Save the Children is the leading, independent organization that creates lasting change for children in need in the United States and 120 countries around the world.

NEW YORK, NY–(Marketwire – November 29, 2010) – MedLink (OTCBB: MLKNA), a leading provider of health information technology solutions, today announced that it has closed an aggregate of $2.25 million in financing. Aegis Capital Corp, sole placement agent and exclusive investment banker to MedLink, placed $1.0 million through a private placement, and an additional $1.25 million in capital through the sale of convertible notes sold exclusively to institutional investors. The investment capital proceeds will be used to fund increased sales and marketing, working capital needs of the Company, and the acquisition of MedAppz which was announced earlier this month.

“We are extremely pleased to have the support of our investors who affirm our corporate vision, and the overwhelming interest in the offering is a testament to the MedLink team and the cutting edge technology we are providing to the healthcare market,” said Ray Vuono, CEO of MedLink International, Inc. “With this financing, the company is well positioned to deliver its suite of Electronic Health Record (EHR) and Healthcare Information Technology communication platforms, to meet the increasing demand of the industry as healthcare facilities of all sizes are adopting EHR technology to take advantage of the efficiencies and the incentives both on a State and Federal level.”

David Bocchi, Director of Investment Banking at Aegis Capital, said, “MedLink represents a rare and exciting opportunity in a competitive and consolidating space where it continues to demonstrate it has the tools and resources necessary to successfully become an industry leader.” He added, “The management team was instrumental in swiftly securing the capital in a placement with overwhelming investor demand, and we look forward to providing the company with the continued support necessary to assist in its growth.”

About MedLink

MedLink is a healthcare IT company providing the medical community with products and services for the creation, management, and sharing of medical information. The company’s flagship product, MedLink TotalOffice EHR 3.1, a CCHIT Certified® 08 Ambulatory EHR, provides physicians with full EHR and practice management functionality. For more information regarding MedLink’s products and services, please visit www.medlinkus.com.

About Aegis

Aegis Capital is a full-service boutique brokerage operation focused on middle-market corporate finance, research, and valuation services. Aegis actively manages over $2 billion of retail customer assets with over 200 registered representatives in 8 corporate locations. Aegis Capital Corporation was founded in 1984 by Robert Eide, the current CEO and Chairman. Its origins were based on servicing the specific needs of an extremely affluent customer base. For more information, please visit the Aegis website at www.aegiscapcorp.com.

Safe Harbor Statement

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, outlined in our 2009 Annual Report on Form 10-Kavailable through www.sec.gov. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

LOS ANGELES, CA–(Marketwire – November 29, 2010) – Fresh Start Private (OTCQX: CEYY) (PINKSHEETS: CEYY), a leader in the alcohol treatment and rehabilitation industry, today announced that its first facility is operational and able to treat up to 15 patients a day with a potential revenue of $120 Million per year per clinic.

According to the National Institute of Health there are an estimated 17.6 million alcoholics in the USA.

Fresh Start Private’s fully licensed and certified medical facility has three treatment rooms that are each able to process up to five patients per day. As part of the treatment, trained medical doctors insert Fresh Start Private’s exclusively licensed specially formulated biodegradable Naltrexone implant just beneath the skin below the patient’s lower abdominal area.

The FDA approved Naltrexone blocks the part of the brain that “feels” pleasure when patients use alcohol. When these areas of the brain are blocked, patients feel less need to drink alcohol, and they can stop drinking more easily. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient’s physiological needs. The combination of these treatments results in sobriety in nearly 100% of all patients.

Fresh Start Private is the only alcohol treatment program to offer a single-administration, long-acting, Naltrexone implant procedure.

 “At Fresh Start Private we have created a comprehensive recovery program that includes state-of-the-art medical intervention, individually tailored Fresh Start Private Coaching Program sessions, rebuilding of family and friend connections and post-treatment continuing care,” stated Dr. Jorge Andrade, CEO of the Company. “Only through a comprehensive treatment solution can a patient have his/her best chance at recovery.”

There are many benefits to the Fresh Start Program compared to other traditional alcohol treatments. As the Fresh Start treatment is administered on an outpatient basis, there is no need for patients to leave their work and family for any extended period of time. In fact, many in treatment return to work the next day and not even co-workers or family members know they are being treated. The Fresh Start team has the experience to handle all alcohol addiction scenarios. The Fresh Start Private program can be less expensive than many traditional treatment centers.

About Fresh Start Private

Fresh Start Private is an alcohol addiction, alcohol withdrawal, alcohol abuse treatment and alcohol detox rehabilitation company on the leading edge of the alcohol addiction treatment. The Company has an exclusive license on a highly effective treatment (Naltrexone Implant) that delivers therapeutic levels of Naltrexone that significantly reduces patients’ cravings for alcohol.

Please visit http://www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “potential,” “up to,” “estimate,” “over,” “intend,” “can be,” “nearly” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to the ability of Fresh Start to manage product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Fresh Start’s website does not constitute a part of this release.

MUNDELEIN, IL–(Marketwire – November 29, 2010) – Medline Industries, Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost-management prime vendor agreement with Cleveland, Ohio-based St. Vincent Charity Medical Center. The five year agreement is anticipated to save the hospital an estimated $2.5 million over the term of the contract.

St. Vincent’s patient-centered focus on quality has earned them the HealthGrades Distinguished Hospital Award for Clinical Excellence for five consecutive years (2006-2010). In keeping with their focus, the hospital plans to take advantage of the many clinical programs Medline offers including the Pressure Ulcer Prevention Program, the Perioperative Pressure Ulcer Prevention Program and the ERASE CAUTI (catheter-associated urinary tract infection) Program. Each of these evidenced-based programs was designed to help improve quality and safety outcomes, increase patient satisfaction and reduce errors for healthcare facilities.

Under the terms of the contract, Medline is expected to generate more than $10 million in annual medical and surgical product sales from the partnership over the term of the agreement. Under the agreement, Medline will provide its broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages.

Cost savings and customer service were two key factors in making Medline St. Vincent Charity Medical Center’s prime vendor. Medline will drive cost savings to St. Vincent through delivering Medline manufactured products direct to the healthcare facility from Medline’s newly built 300,000 square foot, state-of-the-art distribution facility in Canton, OH. Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About Saint Vincent Charity Hospital
St. Vincent Charity Medical Center is Cleveland’s faith-based, high-quality healthcare provider, with distinguished doctors and caregivers devoted to treating every patient with clinical excellence and compassionate care. St. Vincent Charity Medical Center is home to the renowned Spine and Orthopedic Institute and the Center for Bariatric Surgery. Owned by the Sisters of Charity Health System, St. Vincent Charity Medical Center delivers health for the heart of Cleveland. The Sisters of Charity Health System is a family of hospitals, grant-making foundations, elder care and outreach organizations devoted to healing individual, families and communities. For more information, visit www.stvincentcharity.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

MONTVALE, NJ–(Marketwire – November 29, 2010) – SRS, the leading provider of productivity-enhancing technology and services for high-performance specialty practices today announced that Indiana Hand to Shoulder Center has selected the SRS Unified Desktop™ for its 35 providers. Indiana Hand to Shoulder Center has 6 office locations providing specialized upper extremity treatment to the greater Indianapolis area.

“The value of an integrated package far exceeds the sum of the benefits of the individual parts,” says James J. Creighton, Jr., M.D., Indiana Hand to Shoulder Center. “Accessing PACS images directly from the patient’s chart in the EMR — without having to open another application and toggle back and forth — will be a huge time-saver for me.”

“The efficiency and ease of use produced by incorporating three vital core technologies into one product is invaluable,” says Audra Frezza, Chief Information Officer, Indiana Hand to Shoulder Center. “One of the reasons we chose SRS is its reputation for the highest levels of customer satisfaction, as well as its drive to stay at the cutting edge of technology. The success level achieved by SRS in the Orthopaedic arena is unparalleled.”

“The Unified Desktop is unique in the EMR industry,” according to Evan Steele, CEO of SRSsoft. “The open architecture upon which our EMR software is built allows us to deliver all clinical and business applications through one seamless user interface. The Unified Desktop is just one of the many ways that SRS boosts productivity for high-performance practices like Indiana Hand to Shoulder Center.”

About SRS
SRS is the leading provider of productivity-enhancing EMR technology and services for high-performance specialty practices — with a successful adoption rate unparalleled in the industry. Offered via the Unified Desktop™, the robust EMR, SRS CareTracker PM, and SRS PACS increase speed, free physicians’ time, boost revenue, and heighten patient care and satisfaction. For more information on SRS, visit www.srssoft.com, e-mail [email protected], fax 201.802.1301, or call 800.288.8369.

About Indiana Hand to Shoulder Center
Indiana Hand to Shoulder Center began in 1971 as a private hand surgery practice. Since then, it has grown to become a renowned center of excellence, recognized across the world for their specialization in problems and injuries of the hand, wrist, elbow and shoulder. Now located on the northwest side of Indianapolis, Indiana Hand to Shoulder Center is the largest free-standing facility of its kind in the world. For more information, visit www.indianahandtoshoulder.com.

OMAHA, NE–(Marketwire – November 29, 2010) – RadTrac, an informatics and biotech solutions firm, has created breakthrough radiation dosage tracking technology that will track and prevent unnecessary radiation exposure for patients and limit liability for hospitals. 

Overexposure to radiation can lead to serious health problems including cancer. There are currently standards set by the American Medical Association for radiation limits but no way exists to track how much cumulative radiation a patient receives. 

Patient radiation levels are tracked and monitored through RadTrac’s proprietary Radiation Dosage Tracking System (RDTS) software engine. Before a patient’s exposure level reaches an unsafe amount, health care providers are alerted and can review diagnostic options before exposing that patient to more radiation, making facilities aware of the potential for overexposure. RDTS allows the physician and medical team to concentrate on practicing medicine and make informed decisions about radiation exposure in real-time.

“The RDTS will not only prevent overexposure and track cumulative exposure, but can also be used as a research tool in the future,” said Gena Kriewald, Co-founder and Vice President of Clinical Development. “The educational benefits that come from creating a national database of radiation exposure on a variety of modalities are immeasurable. By sharing dosage level information across a network of hospitals throughout the nation, facilities can learn not only how to limit exposure but also what modalities are most effective while offering the least amount of radiation.”

“We are currently tracking several facilities with various modalities in regions throughout the United States,” said RadTrac Chief Executive Officer Jesse Fisher. “The RadTrac system takes a proactive approach to preventing radiation exposure by tracking the amount of radiation patients are exposed to — both at the procedure level and cumulatively — and alerting medical professionals before high levels of radiation exposure are reached.”

RadTrac implemented the initial phase of RDTS testing in March of 2010, and completed beta testing in June. The product is now available for release.

About RadTrac: RadTrac is a joint venture of Binovia, Inc., an informatics and biomedical services firm, and Study Overflow Solutions, Inc., (SOS), a teleradiology and practice management firm. RadTrac, a radiology software solutions firm, provides systems and implementation to medical facilities including hospitals, radiology departments and clinics to prevent radiation overexposure and promote x-ray and radiation safety. 

WOBURN, MA–(Marketwire – November 29, 2010) – Yankee Alliance (www.yankeealliance.com), a Group Purchasing Organization for Healthcare industry member organizations, has approved Service Point USA (www.servicepointusa.com) as a vendor for the provision of Large Format Graphics and Signage.

There are 69 YA member organizations which consist of Hospitals and Medical Centers. These are located primarily in the Northeast region of the U.S. where Service Point USA’s service center locations are concentrated.

In addition, YA has thousands of Affiliate Members throughout the U.S. that include Long Term Care Facilities, Clinics, Rehabilitation Facilities, and other Healthcare related businesses. These are potential users of Service Point’s products and services as well.

Member buyers include multiple professionals from each organization in departments of Marketing and Communications, Public Relations, Purchasing, Training and Education, and Facilities Management groups.

Service Point is unique among YA vendors with its specialization in Large Format Graphics, Signage, and Way Finding Systems. Example applications of these products and services for the Healthcare industry include:

• Facility Way / Finding signage systems, interior and exterior
• Educational / Public Relations Displays
• Environmental Graphics / Murals / Posters
• Eco-Friendly Display Graphics
• Information Graphics / HIPAA Communication Posters
• Clean Room / Laboratory moisture-resistant posters and safety signs
• Floor Graphics and Way Finding visual aids
• Event Banners and Flags
• ADA Compliant Signage
• Vehicle Graphics, Vinyl Lettering

YA buyers may send orders and graphic files for production electronically via their unique, online Digital Storefront site established by Service Point for the use of YA members only. Service Point’s Digital Storefront product provides authorized users a secure and efficient means to transmit and store files for future access within a custom branded environment.

The Yankee Alliance agreement augments Service Point USA’s continued pursuit of business within the Healthcare industry, one of its focus markets.

About Service Point
Service Point provides tools and services for greater efficiency in document, print, and information management via networked service centers, online, and through On-Site Services programs with client firms nationwide.

Service Point USA is a subsidiary of Service Point Solutions. It employs 2,400 people across 8 countries through a network of 127 service centers and 794 facilities management programs. SPS is headquartered in Spain and listed on the Madrid and Barcelona stock exchanges (ticker: SPS.MC).

SEATTLE, WA–(Marketwire – November 29, 2010) – With changing consumer expectations and the increased use of mobile devices, healthcare organizations need to find ways to engage members and patients in new ways. But, if achieving behavioral change was as simple as sending a text message, everyone would be eating a healthy diet, exercising regularly and would never smoke.

In this complimentary Webinar, Dr. George Gellert, senior healthcare advisor for Varolii Corporation, and Elizabeth Boehm, principal analyst at Forrester Research, will share insights into how healthcare consumers’ expectations are changing and how healthcare organizations can use mobile devices to engage members and patients in an effective way.

WHEN: Thursday, December 2, 2:00 – 2:45 p.m. ET / 11:00 – 11:45 a.m. PT

WHAT: A complimentary Webinar discussing why patient communications are critical to changing patient behaviors. Attendees will learn:

• How patient preferences impact the effectiveness of communications
• How to improve program adherence with a cross-channel communication strategy
• Why patient communications will be critical to achieving healthier outcomes

WHO: Dr. George Gellert, MD, senior healthcare advisor for Varolii, is a physician epidemiologist and executive with 20 years of experience in health information and communication. Dr. Gellert is the former Chief Medical Officer and EVP for HCORP Inc. and Senior VP of Strategic Alliances at WebMD. 

Elizabeth Boehm, principal analyst at Forrester Research, joined Forrester in 1997 and became co-founder of Forrester’s healthcare and life sciences practice in 1999. She continues to lead the healthcare and life sciences research community, and her own research focuses heavily on the topic areas relevant to healthcare customer experience.

REGISTER: https://www.varolii.com/en/go/2010/smshcwebinar

BURBANK, CA–(Marketwire – November 29, 2010) – Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today provided insight into the Company’s strategy for resubmission to the FDA.

“After reviewing with our FDA counsel our prior application, files, images and recent FDA correspondence, Imaging3 plans to resubmit its application for clearance of the Dominion Vi Scanner under the FDA’s 510(k) process,” stated Dean Janes, Chairman and CEO of Imaging3, Inc. According to Mr. Janes, “The results of our review with counsel has determined that the 510(k) program remains the most appropriate and efficient route for FDA approval. It was determined that the ‘De Novo’ and ‘PMA’ processes were not necessary and with some minor adjustments to our existing package along with some additional information and potentially a pre-submission meeting with the FDA, the 510(k) submission should be successful. I am confident that with the assistance of our newly hired FDA consultants and our new strategy we will be able to provide the Agency with a package that meets their needs to expeditiously approve our device,” Mr. Janes added.

About Imaging3
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at www.imaging3.com

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

MANCHESTER, UNITED KINGDOM–(Marketwire – Nov. 29, 2010) – Bromsgrove based cosmetic surgery provider The Hospital Group, has announced the acquisition of Manchester based cosmetic surgery clinic, SurgiCare, after it bought the company out of administration.

The move secures The Hospital Group as the number one cosmetic surgery provider in Europe, with a network of 27 clinics situated across the UK and Ireland plus over 10 in Spain. The Group also expanded into the USA in 2009 with a base in Los Angeles.

Choosing to retain the SurgiCare brand independently, The Hospital Group and SurgiCare will tackle different areas of the market to gain a complimentary business strategy.

The deal has secured the jobs of 37 workers and follows the group’s recent acquisition of NU Age medical Spa in Newcastle Upon Tyne.

David Ross, Chief Executive at The Hospital Group, said: “This business deal shows the company’s commitment to consolidating and building our position in the UK and international market.

“Many people are struggling to find work in this tough economic climate but this partnership has helped to save jobs as well as open doors and create more opportunities.

“We are really excited about the potential that this opportunity has given us. There will doubtless be synergy and development on both sides.”

The Hospital Group are one of the UK’s leading providers of cosmetic surgery, providing cosmetic, dental and weight-loss solutions for thousands of patients every year. 

Since The Hospital Group was established in 1992, it has grown to become one of the world’s foremost cosmetic and weight loss surgery providers.

The flagship hospital, Dolan Park, is the largest specialist facility of its kind in the UK, dedicated to cosmetic and obesity surgery. All surgeons are GMC registered and cosmetic consultations are performed free of charge, with a lifetime free aftercare package included.

PALO ALTO, CA–(Marketwire – November 28, 2010) – Fovia, Inc., a leader in volume rendering technology, has demonstrated the scalability of its High Definition Volume Rendering® software on the newest generation of Apple® computers. Fovia’s HDVR® software performed 1.5x faster on a Mac Pro 12-core 2.93GHz than it did on a Mac Pro 8-core 2.93GHz (Apple’s previous generation), thereby showcasing perfect, core-for-core scalability. The benchmarking results can be found on Apple’s website at http://www.apple.com/macpro/performance.html.

Fovia’s HDVR algorithms and architecture take full advantage of the future directions in both imaging and computing (larger datasets, larger projection displays, multi-core processors, multi-threading, multi-CPU environments and server-side rendering for thin-clients) without sacrificing quality or performance. This scalability has been, and will continue to be, critical to ensuring the long-term superiority of Fovia’s solution. 

George Buyanovsky, Fovia’s President and C.T.O., remarked, “The highly-efficient multi-core scalability of HDVR has been a major focus of Fovia’s rendering technology. Our CPU-based Volume Ray Casting algorithms very effectively utilize available CPUs resources; therefore, the evolution of general purpose CPUs toward multi-cores and multi-threading are increasingly beneficial for our clients, and we are pleased that our benchmarking results have been published by such a well-respected third party.”

Fovia’s scalable, software-only solution has unparalleled interactive image quality, superior performance, and better memory utilization than other products currently available — including expensive, hardware-based approaches. In addition to its extraordinary scalability with respect to processor performance, Fovia’s HDVR® engine scales with both the exponentially increasing amount of data being generated by modern scanners, and with the continuing growth of larger and higher definition displays now being used for more accurate viewing.

About Fovia, Inc.

Fovia, Inc. was founded in 2003 to address the challenges of data explosion — the exponentially increasing amount of data being acquired by modern imaging modalities. The firm has developed a CPU-based, High Definition Volume Rendering® software solution that leverages and scales with multi-core, multi-processor and multi-threaded generational processor development. Fovia’s HDVR® solution is more scalable, cost effective, flexible, and easily deployable on an enterprise-wide basis than GPU or other hardware-based approaches and can be easily and natively integrated into various original equipment manufacturers’ offerings, therefore allowing OEMs to quickly and cost-effectively offer the world’s most advanced volume rendering to their customers.

For additional information, visit www.fovia.com.

Apple is a registered trademark of Apple Inc.

Fovia, High Definition Volume Rendering and HDVR are registered trademarks of Fovia Inc.

FOSTER CITY, CA–(Marketwire – November 27, 2010) – TeraRecon, Inc. (www.terarecon.com), a global leader in advanced visualization and decision support solutions, has received the North American Growth Leadership of the Year Award in the category of Advanced Visualization and Clinical Applications by the respected independent research firm Frost and Sullivan. This award represents the sixth time in the past 10 years that TeraRecon, Inc. has been recognized with an award from Frost and Sullivan. It is the second time in 2010, following the European Company of the Year Award in the category of Medical Imaging, Advanced Visualization Applications. The full text of the new award can be reviewed on the company’s website at www.terarecon.com/fs2010-2.pdf

The Award is issued contemporaneously with the release of the new Frost and Sullivan market research report on the North American advanced visualization market, and is derived from independent and objective research performed by the Frost and Sullivan team, which was not commissioned or funded by TeraRecon. The research was based on two independent primary research efforts conducted during the last year by Frost & Sullivan researchers, each focused on decision makers for advanced visualization in the United States.

Quoting from the text of the Frost and Sullivan award, “In more than one aspect, TeraRecon has become the leading independent vendor in the North American advanced visualization industry today.” The award noted that TeraRecon is “…capturing a higher market share than all other vendors within its tier of competition” and also recognized the company’s focus on the role and potential of advanced visualization in the healthcare enterprise: “Indeed, TeraRecon’s solutions achieve the highest ratings with regard to their remote access and integration capabilities, making TeraRecon the market leader for delivering advanced visualization enterprise-wide.”

The research also revealed that TeraRecon is perceived as the vendor offering the most advanced technology and the highest performance, that TeraRecon obtained the highest ratings for customer satisfaction, and that the surveyed respondents rated TeraRecon’s solution with the highest ratings for ease of use.

Frost and Sullivan made particular note of iNtuition™ CLOUD, stating “The cloud-based solution launched recently by TeraRecon is yet another illustration of the company’s edge with technology and its ability to react swiftly to emerging industry trends and customer needs.”

Furthermore, the value of the company’s investment in research and development of clinical applications was acknowledged with the observation that “TeraRecon achieved the highest ratings among independent vendors not only from a technology standpoint, but also from a clinical standpoint.”

TeraRecon President & CEO Robert Taylor, Ph.D. commented on the award, “We are truly honored to have received a sixth Frost and Sullivan award — the second within a single year, now recognizing the company’s achievements in the North American market, following up on the recognition we received from Frost and Sullivan earlier in the year relating to our innovative business strategy in Europe. This independent research by Frost and Sullivan objectively proves what we have always strived for relating to our customers’ appreciation of our products’ performance, our customer service, our clinical excellence, and our commitment to enterprise workflow and integration with other informatics systems. The accompanying report also highlights that TeraRecon’s enjoys the highest attachment and integration rate to PACS systems deployed in the North American market, as further evidence of the company’s commitment to a radiologist-centric workflow.”

Dr Taylor continued, “TeraRecon is more committed than ever to innovation and technological and clinical excellence. We are defining new boundaries for advanced visualization every day, as our new iNtuition CLOUD offering gains more and more registered users and the clinical capabilities of iNtuition expands rapidly. We believe that the future of medical imaging will inevitably consist of a combination of on-site software, cloud-based hosting, and meaningful integration with other enterprise healthcare informatics systems, and we embrace this challenge with the greatest enthusiasm and commitment.”

Free evaluation accounts for iNtuition CLOUD can be obtained at terarecon.com/cloud.

About TeraRecon (www.terarecon.com)
TeraRecon is a global leader in advanced image processing, decision support and 3D visualization techniques. The company’s solutions provide advanced imaging support for medical and other visualization applications based on its unique and patented image processing technologies. A six-time winner of Frost and Sullivan awards, the company has developed a leading portfolio of products that advance the performance, quality, functionality, and integration of image processing and 3D visualization systems since its founding in 1997. TeraRecon is a privately held company with headquarters in Foster City, California, USA, European headquarters in Frankfurt, Germany, and branch offices in Concord, Massachusetts, USA and Tokyo, Japan.

About Frost & Sullivan:
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com

iNtuition™ is a trademark of TeraRecon, Inc.

ALEXANDRIA, VA–(Marketwire – November 26, 2010) – Mortality rates for people with type 1 diabetes are decreasing, but overall remain seven times higher than those of the general population — likely as a result of long-term complications, a study in the December issue of Diabetes Care reports.

And while there were no significant differences in mortality rates between genders, women with type 1 diabetes were 13 times more likely to die than women who did not have diabetes, reported researchers from the University of Pittsburgh. Also in this study, part of the Epidemiology Research International Study Group, a much higher proportion of African Americans (50.6 percent) died than Caucasians (24 percent).

“It’s unclear why, for both women and African Americans, type 1 diabetes has such a major effect compared to the general population,” said Dr. Trevor Orchard, senior author of the study. “This greater effect of diabetes for women is not seen as strongly in studies in other parts of the world. One thing that is clear is that we need to pay special attention to their care and treatment and continue to investigate why they might be disproportionately impacted by the long-term consequences of this disease.”

Overall, mortality rates for people with type 1 diabetes fell significantly in this community-based population from Allegheny County, PA, over the past several decades, the study found. For those diagnosed between 1965 and 1969, mortality rates were 9.3 times higher than the general population. However, for those most recently diagnosed (1975-1979), the rate was just 5.6 times higher, showing a clear decline.

“It looks like the main improvement in those most recently diagnosed is related to dramatically reducing mortality in the first five years after diagnosis,” said Dr. Aaron Secrest, lead author of the paper. “We think it’s probably a result of better management and awareness of diabetes control, leading to providers and patients doing a better job of monitoring for acute complications.”

Overall, reductions in mortality are most likely due to the tremendous improvements in treatment and care during the 1980s and 1990s, the researchers noted. In particular, blood glucose self-monitoring, A1C testing and use of new blood pressure medications such as angiotensin-converting enzyme inhibitors, which also help protect against diabetic kidney disease. These changes have greatly improved both blood sugar and blood pressure control, often the cause of life-threatening complications.

The study looked at people in Allegheny County the Pittsburgh area who had type 1 diabetes diagnosed as a child between 1965 and 1979 and at the time of analysis had a duration of diabetes between 28 and 43 years, and explored differences in mortality based on sex, race (Caucasian vs. African American) and year of diagnosis.

For more information, please contact Dr. Trevor J. Orchard, University of Pittsburgh, Department of Epidemiology, Graduate School of Public Health, at email: [email protected] or call 412-383-1032.
To contact Dr. Aaron Secrest call 940-597-1991.

Diabetes Care, published by the American Diabetes Association, is the leading peer-reviewed journal of clinical research into one of the nation’s leading causes of death by disease. Diabetes also is a leading cause of heart disease and stroke, as well as the leading cause of adult blindness, kidney failure, and non-traumatic amputations.

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

VANCOUVER, BRITISH COLUMBIA–(Marketwire – Nov. 26, 2010) – The BC Medical Journal, BC doctors’ flagship medical journal, has completely revitalized its online presence. Beginning today, www.bcmj.org will not only continue with its tight focus on medical stories and advancements that occur in British Columbia, but will be adding the more dynamic qualities that the web is known for. 

BCMJ.org expanded upon its current website, which historically has simply provided the new monthly printed journal in an online method, by also including: 

• Video content linked to clinical articles in the journal that will incorporate related surgical videos and author interviews
• Health Notes for doctors and patients that will provide printable tips to improve your health on topics such as dealing with depression, reducing stress, and dementia, as well as reliable patient information related to clinical articles published in the BCMJ.
• Interactive content such as a blog in which physicians can interact with each other and members of the public and the ability to comment directly on published articles.
• A “people” section focusing on physician authors in the BCMJ, physicians who go above and beyond the call of duty, and stories about physicians’ own experiences in life.

“With the launch of our new website, the BCMJ takes giant leap forward in the brave new world of electronic communication. As the online home of BC physicians, we strive to keep doctors connected while providing them with fresh and relevant medical content,” says the BCMJ’s editor, Dr. David Richardson. 

The new interactive website is open to physicians in BC – and physicians around the globe – as well as all members of the public.

The British Columbia Medical Journal is a general medical journal featuring primarily scientific research, review articles, and updates on contemporary clinical practices written by British Columbian physicians or focused on topics likely to be of interest to them, such as columns from the BC Centre for Disease Control and ICBC. The print BCMJ is issued ten times each year, while bcmj.org will release stories throughout the month. The journal is peer reviewed and edited by an Editorial Board consisting of physicians from varying disciplines. Although it is published by the BC Medical Association (BCMA), it maintains distance from the BCMA in order to encourage open debate. It also hosts an online database for all BCMJ issues dating back to 2000.

LAS VEGAS, NV–(Marketwire – November 26, 2010) – Fresh Start (OTCBB: CEYY) announces it appointed Dr. Jorge Andres as CEO and Director of the company.

Effective November 22, 2010, Michael Cetrone resigned as President and Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and as a member of the Board of Directors of Fresh Start Private Management, Inc. (the “Company”).

Concurrent with Mr. Cetrone’s resignation, Dr. Jorge Adrade, was appointed Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer. Dr. Andrade was already a member of the Board of Directors of the Company.

Dr. Jorge Andrade Jr. is founder, CEO and President of West Coast Consulting Inc. since 2004. Dr. Andrade is a licensed Doctor of Dental Surgery and National Dental Board Certified since 1998. One of Dr. Andrade’s current positions is Senior Program Co-coordinator for the Western Division of Colgate Palmolive “Bright Smiles Bright Futures Dental Program.” Dr. Andrade is a Licensed Medical Interpreter, a licensed Doctor of Dental Surgery since 1995, and co-founder of TM Cube Medical LLC. Dr. Andrade has exceptional knowledge of starting, building and managing small businesses.

Effective November 22, 2010 the Board of Directors appoints Neil Muller as President.

Neil Muller is one of the world’s leaders in alcohol treatment and recovery and the architect of the Fresh Start Private Program. Mr. Muller has treated over 5,000 patients worldwide and will now focus his efforts on directing the clinics in America to cure the 18 million alcoholics across the country.

About Fresh Start Private™

Fresh Start Private is a company on the leading edge for the treatment of alcohol addiction. The Company’s founder has treated over 5,000 patients. Fresh Start is the only alcohol treatment program in the world to offer a single-administration, long acting, Naltrexone implant™. The non-invasive Naltrexone implant is placed just under the skin in the patient’s abdominal area. The procedure takes about 20 minutes and in nearly every instance patients are released the same day.

For more information, visit www.freshstartprivate.com.

Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in Fresh Start filings with the Securities and Exchange Commission. 

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – Across Ontario, care for seniors is being compromised by a spate of hospital bed and program cuts and the transfer of elderly ill patients to sub-standard, unregulated care in retirement homes or to languish alone in their homes.

In Windsor, a 93 year old woman, who has two months to live, has been told to move out of the hospital or pay $600 a day to remain. She is the human face of elderly patients who are demeaned as “bed blockers.”

In Scarborough, Providence Continuing Healthcare is cutting 120 beds a move that will adversely affect many programs including patient rehab, and palliative and chronic care.

In Sudbury, the Regional Hospital’s Memorial site is closing—128 beds will be lost and frail seniors are being moved.

This pattern of hospital service cuts is happening across Ontario and services for the frail and the elderly are the primary target.

Across Ontario, home care is in chaos, with a 57% annual turnover of caregivers and with hours of care more and more difficult to access.

“We believe that the elderly are being discriminated against in the provision of care. Hospital, long- term care and home care workers have had enough of the attack on services for seniors. Our protest today is the beginning of our push back. We are asking for dignity in care for the elderly. We are asking for their right to spend their last days in palliative care in hospital. We demand an end to the pushing of the frail and the ill into unregulated retirement homes or to home alone,” says Michael Hurley, the president of the Ontario Council of Hospital Unions. 

Rally information is as follows:

Rally speakers include:

Paul Moist, President, Canadian Union of Public Employees, Arlene Patterson, Chair of the Sarnia Lambton Health Coalition, and hospital, long-term care and home care workers.

PANAMA CITY–(Marketwire – November 25, 2010) – The Stem Cell Institute (www.cellmedicine.com) reported today recovery of a spinal cord injury patient that was treated with a unique combination stem cell treatment. The patient suffered a crush fracture of the L1 vertebral body on May 13^th, 2008 after a single propeller engine airplane crash. As a result of the spinal cord injury, the patient had severe neuropathic pain, loss of sexual and bladder function, as well as loss of movement and sensation in the legs. 

He was treated on Oct 31-Nov 20, 2008, Jan 21-30, 2009, and July 1-10, 2009 with an adult stem cell protocol. The patient underwent a progressive recovery of sensation, mobility, and sexual and bladder function subsequent to each cycle of stem cell administration. Currently the patient is capable of walking and neuropathic pain diminished substantially.

“The doctors at the Stem Cell Institute have changed my life. After the accident there was no hope. Now I have a new lease on life,” said Juan Carlos Murillo Rodriguez, the patient who was treated. “I have recently passed my physical and am flying again as a commercial pilot.”

Details of the scientific rationale for the treatment, as well as protocols and outcomes may be found in the peer-reviewed paper “Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report” which was published in the International Archives of Medicine and is available online at http://www.intarchmed.com/content/pdf/1755-7682-3-30.pdf.

“It is my honor that such a team of internationally recognized opinion leaders in the area of stem cells such as Doctors Amit Patel, Michael Murphy and Thomas Ichim have co-authored this publication,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and co-author of the publication. “By combining our clinical experience with cutting-edge advances in molecular and cellular biology, we believe we have put forth a very innovative protocol that we anticipate will be attempted by other groups.”

About Stem Cell Institute

Stem Cell Institute is one of the leading adult stem cell research and treatment centers in the world. Using our pioneering treatment methods and utilizing partnerships with universities and physicians across the world, Stem Cell Institute has already treated over 800 patients with stem cell therapy and the company continues to expand. Stem Cell Institute is located in Panama City, Panama.

id=”nav_links”>

TORONTO, ONTARIO–(Marketwire – Nov. 25, 2010) – With aging baby boomers making up nearly a third of Canada’s population, the $1.2 billion natural health product industry has naturally caught the eye of well known entrepreneur and strategic investor W. Brett Wilson. Through his involvement with Dragons’ Den, Wilson has committed to a $250,000 investment in NuvoCare Health Science Inc., a company with a portfolio of health brands designed to sustain youth and longevity and prevent disease.

The company was founded by Ryan J. Foley, a food scientist and pharmacologist who has designed a clinically proven composition called AgeOFF® designed to stop the DNA damage that leads to cancer and is the primary culprit behind human aging.

Having battled an advanced state of prostate cancer at 43, Wilson has made personal health his number-one priority, a core philosophy that is shared by NuvoCare. An estimated 173,800 Canadians will be diagnosed with cancer this year with approximately 76,200 of those cases resulting in death.

“This is as much a personal investment as a financial one,” said Wilson, who is also a daily product user. “I know too many people who are fighting cancer, and too many who have fought it and lost. It’s gratifying to support a company focused on reversing this negative trend.”

NuvoCare is also in conversations with the federal government to explore how their products can help reduce the upward pressure on federal-provincial health care spending, expected to grow significantly as more baby-boomers become seniors. On average, seniors consume five times more health-care dollars than younger adults. NuvoCare products help seniors stay healthy, decreasing their consumption of health-care dollars. The first baby-boomers will turn 65 on January 1, 2011.

“Brett has a passion for our work and a brilliant marketing mind able to help us reach more people and keep them healthy,” said Foley who added that NuvoCare is in a strong position to tap into a large percentage of Canada’s natural health product industry over the next three years.

NuvoCare was in established in 2006 by Foley after 10 years of corporate research and development experience in the nutraceutical industry. “I wanted to align myself with my higher life purpose of health sustainability and I built NuvoCare to realize this potential,” says Foley. NuvoCare’s products help to decrease body weight safely, prevent loss of muscle and bone, decrease the appearance of wrinkles and fine lines, and improve sleep quality, to name just a few of their benefits. NuvoCare’s portfolio of health brands includes AgeOFF® (www.AgeOFF.com), SleepON® (www.SleepON.com), WeightOFF® (www.WeightOFF.ca), DNA-Essentials® (www.DNAessentials.ca), and Skin-Minus® (www.SkinMinus.com).

NuvoCare Health Science Inc. is a Canadian owned and operated company whose sole focus is to design and develop the worlds safest and most effective nutraceutical, nutricosmetic, and cosmeceutical brands clinically proven to address the major health concerns of today’s consumer using proven natural ingredients of the highest safety, efficacy and quality standards. www.NuvoCare.com.

W. Brett Wilson is Chairman of Canoe Financial, a privately owned investment management firm with over $1.5 billion in assets focused on providing investors with unique opportunities to profit from Canada’s increasing prominence on the global stage. He is also Chairman of Prairie Merchant Corporation; a private merchant bank focused on business opportunities in the energy, agriculture, real estate, sports, and entertainment industries. In 1993, he co-founded FirstEnergy Capital Corp., a Canadian brokerage firm that provides investment-banking services to Canada’s oil and natural gas sector. FirstEnergy is an industry leader, having participated in thousands of financing and M&A projects worth over $225 billion. After retiring from active duty in 2008, Brett remains an investor in the firm.